Circulation 8 2026 Semaglutide and the Inflammatory Pathways to Cardiovascular Health

This study explores how the medication semaglutide reduces the risk of major heart-related events by targeting chronic inflammation in patients with cardiovascular disease. Researchers tracked a specific protein marker, hsCRP, and discovered that lowering this indicator significantly improved patient survival regardless of initial weight or cholesterol levels. Crucially, the drug’s ability to dampen the inflammatory responsehappened rapidly and functioned independently of weight loss, suggesting the treatment protects the heart through multiple biological pathways. Ultimately, the findings highlight that semaglutide’s success in preventing strokes and heart attacks is driven largely by its potent anti-inflammatory effects.